Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 16/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13430007 | 0.84 | P2RX7 (0.42) | P2RX7 | |
| SCHEMBL13430047 | 0.84 | NOTUM (0.43) | NOTUMP2RX7 | |
| SCHEMBL13430013 | 0.81 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL20639902 | 0.77 | NOTUM (0.70) | NOTUML3MBTL1KDM4EMAPTP2RX7 | |
| SCHEMBL13429783 | 0.76 | GRIN1 (0.45) | P2RX7 | |
| SCHEMBL13430089 | 0.76 | BRD4 (0.39) | NOTUMKDM4EMAPTP2RX7 | |
| SCHEMBL13429988 | 0.76 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL27163069 | 0.74 | NOTUM (0.60) | NOTUML3MBTL1KDM4EMAPTP2RX7 | |
| SCHEMBL15578550 | 0.74 | KDM4E (0.53) | NOTUMKDM4EP2RX7 | |
| SCHEMBL20574715 | 0.74 | RAB9A (0.49) | NOTUML3MBTL1KDM4EMAPTP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| CN-108779094-B | Metalloenzyme inhibitor compounds | NQP 1598公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2021-04-29 | — | — | US | disclosed |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2020-03-12 | — | — | US | disclosed |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2018-12-06 | — | — | US | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| EP-2134721-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | Micurx Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| EP-1699784-A4 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2008-09-03 | — | — | EP | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| CN-1894242-A | Novel oxazolidinone derivatives | DONG A PHARM CO LTD (KR) | 2007-01-10 | — | — | CN | disclosed |
| EP-1699784-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | Dong-A Pharmaceutical Co., Ltd. (KR) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005058886-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | IDO1, IDO2, INMT | NOTUM 3300/4885L3MBTL1 3059/4885KDM4E 3464/4885 |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NOTUM 1126/4885L3MBTL1 1568/4885KDM4E 3322/4885 |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | NOTUM 1126/4885L3MBTL1 1568/4885KDM4E 3322/4885 |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | NOTUM 1253/4885L3MBTL1 2599/4885KDM4E 2360/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | NOTUM 1802/4885L3MBTL1 2223/4885KDM4E 950/4885 |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | NOTUM 1253/4885L3MBTL1 2599/4885KDM4E 2360/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | NOTUM 1886/4885L3MBTL1 3352/4885KDM4E 2578/4885 |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | NOTUM 1253/4885L3MBTL1 2599/4885KDM4E 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.